Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products

By sieving and optimizing coating ratios, and applying mechanical stress to deform coating materials, the agglomeration of API particles is minimized, ensuring stable disintegration and dissolution rates in pharmaceutical compositions.

JP2024157034AActive Publication Date: 2024-11-06CATALENT U K SWINDON ZYDIS LIMITED

Patent Information

Application Number
JP2024139653
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-22
Filing Date
2024-08-21
Publication Date
2024-11-06
Estimated Expiration
2040-02-21

Smart Images

  • Figure 2024157034000001_ABST
    Figure 2024157034000001_ABST
Patent Text Reader

Abstract

To provide pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods.SOLUTION: Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize an amount of excess unbound coating material. Specifically, a coating ratio and / or a dosing ratio can be used to minimize a residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65 to 85%w / w API particles; 15 to 30%w / w coating material coating the API particles; and 3 to 15%w / w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25°C and at least 60% relative humidity.SELECTED DRAWING: Figure 4
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 809,307, filed February 22, 2019, the entire contents of which are incorporated herein by reference.

[0002] It relates to a process for coating active pharmaceutical ingredient (API) particles, and more specifically to a process that minimizes excess coating material to prevent clumping of the coated material in lyophilized oral disintegrating dosage forms during storage. [Background technology]

[0003] A pharmaceutical composition typically contains both an active pharmaceutical ingredient as well as one or more inactive ingredients. The active pharmaceutical ingredient (API) is biologically active and is designed to directly affect a patient's symptoms, disease, disorder, and / or illness. On the other hand, the inactive ingredient(s) of a pharmaceutical composition are pharmacologic inactive and may be used for a variety of purposes, including, but not limited to, improving long-term stability, filling or diluting solid formulations, promoting drug absorption, adjusting the viscosity of liquid formulations, improving solubility, and / or aiding in the manufacture of the pharmaceutical composition.

[0004] In addition, some inactive ingredients can be used to mask the taste of the API. Many APIs are known to exhibit unpleasant organoleptic properties, such as bitterness, burning, and numbness, when dissolved in the oral cavity. For example, some orally administered pharmaceutical compositions are designed to disperse in the mouth to allow administration without water, targeting pediatric patients, geriatric patients, veterinary patients, and / or other types of patients who may have difficulty swallowing. For these types of orally administered pharmaceutical compositions, inactive ingredients can be used to form a "functional coating" to mask the taste of the API.

[0005] For example, inactive ingredients may be used to mask the taste of the API by wet or dry coating the API particles to produce a functional coating that surrounds the API particles and prevents release of the API in the mouth. In wet particle coating, the inactive ingredients (polymers and additives) are dissolved or dispersed in a solvent or water to form a suspension or solution. This suspension or solution can then be sprayed onto the surface of the API particles and evaporation of the solvent or water can form a film coating. Examples of techniques for wet particle coating include microencapsulation, fluid bed coating, spray drying, pan coating, etc. In dry particle coating (also called solventless coating), the API particles are physically coated with fine particles of the inactive ingredients (polymers and additives) to form a particle composite. Examples of dry particle coating include hot melt coating, supercritical coating, impaction coating, electrostatic coating. API particles coated with taste-masking inactive ingredients can provide a more pleasant experience for patients who have difficulty swallowing or have sensitivities to tastes that would otherwise result in a negative patient experience and poor compliance.

[0006] For example, dry, solvent-free mixing methods may use high energy vibrations or acoustic resonance to mix the API with the inactive ingredient(s). Additionally, coating the API particles with a functional coating can temporarily delay the release of the API in the patient's mouth during dispersion of the pharmaceutical composition, yet still allow at least 90% of the API that would be released without the coating to be released from the functionally coated API within a suitable amount of time for absorption. Coating the API in a taste-masking inactive ingredient can control the dissolution rate of the coated API particles, ensuring that the majority of the coated API particles are not released until after the coated API particles have entered the patient's stomach. Summary of the Invention [Problem to be solved by the invention]

[0007] Methods are provided for minimizing agglomeration of coating materials for coated API particles produced using various mixing processes. API particles coated using conventional mixing processes often experience excessive coating material agglomeration, especially upon storage. Agglomeration of coating materials can reduce the stability of a pharmaceutical product over time. For example, the disintegration time of a pharmaceutical product may increase over time if it contains an agglomerated coating material. An increase in disintegration time and / or a decrease in dissolution rate indicates an unstable pharmaceutical product. An unstable pharmaceutical product may result in a shorter than desired storage period. Thus, the provided embodiments help minimize agglomeration of coating materials for coated API particles, which can improve the stability of a pharmaceutical product during storage and increase its shelf life.

[0008] For example, the described methods include removing excess coating material from the coated API particles to minimize the possibility of agglomeration of the coating material particles. In particular, the provided methods include sieving the coated API particles so that the final drug product is properly surrounded by a dry matrix, minimizing any agglomeration of the coating material particles during storage. The described pharmaceutical compositions provide disintegration times and dissolution rates that remain relatively stable over time. [Means for solving the problem]

[0009] In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising 65-85% w / w API particles, 15-30% w / w of a coating material coating the API particles, and 3-15% w / w of a matrix surrounding the coated API particles, the pharmaceutical composition comprising a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 25° C. and at least 60% relative humidity. In some embodiments, the coating material comprises a first coating material and a second coating material, the pharmaceutical composition comprising 10-30% w / w of the first coating material and 0.5-10% w / w of the second coating material. In some embodiments, the first coating material comprises a wax. In some embodiments, the second coating material comprises silica. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 30° C. and at least 65% relative humidity. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 40° C. and at least 75% relative humidity. In some embodiments of the pharmaceutical composition, the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent. In some embodiments of the pharmaceutical composition, the coating material comprises silica as one or more of a protective agent or flow aid. In some embodiments of the pharmaceutical composition, the coating material comprises a wax. In some embodiments of the pharmaceutical composition, the coating material comprises one or more of carnauba wax, candelilla wax, or a synthetic wax. In some embodiments of the pharmaceutical composition, the coating ratio used to combine the API particles with the coating material comprises 5-85% w / w coating material and 15-95% w / w uncoated API particles. In some embodiments of the pharmaceutical composition, the matrix comprises a matrix forming agent and a structure forming agent. In some embodiments of the pharmaceutical composition, the matrix forming agent comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.In some embodiments of the pharmaceutical composition, the matrix forming agent comprises a polypeptide. In some embodiments of the pharmaceutical composition, the polypeptide comprises gelatin. In some embodiments of the pharmaceutical composition, the structure forming agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin. In some embodiments of the pharmaceutical composition, the structure forming agent comprises mannitol.

[0010] In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition being prepared by a process comprising: coating API particles with a first coating material to form coated API particles, the coating material comprising one or more deformable components; applying a mechanical stress to the coated API particles to deform the one or more deformable components; coating the coated API particles with silica, the mechanical stress to embed the silica in the coated API particles; sieving the coated API particles to remove excess coating material, the excess coating material comprising coating material not bound to the coated API particles; mixing the coated API particles in a matrix solution / suspension to form a pharmaceutical suspension; and administering the pharmaceutical suspension into a mold, the pharmaceutical composition comprising a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 25° C. and at least 60% relative humidity. In some embodiments of the pharmaceutical composition, the dosing ratio used to combine the coated API particles with the matrix solution / suspension comprises 5-60% w / w of coated API particles to 40-95% w / w of matrix solution / suspension. In some embodiments of the pharmaceutical composition, the coating ratio used to combine the API particles with the coating material comprises 5-85% w / w of coating material and 15-95% w / w of uncoated API particles. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises freezing the administered suspension under sub-zero conditions and lyophilizing to form a lyophilized pharmaceutical composition. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 30° C. and at least 65% relative humidity. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises a disintegration time of less than 10 seconds for at least 6 months under storage conditions of at least 40° C. and at least 75% relative humidity.In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises 65-85% w / w API particles. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises 15-30% w / w coating material. In some embodiments of the pharmaceutical composition, the pharmaceutical composition comprises 3-15% w / w matrix. In some embodiments of the pharmaceutical composition, the method used to prepare the pharmaceutical composition comprises sieving uncoated API particles. In some embodiments of the pharmaceutical composition, sieving the coated API particles comprises passing the coated API particles through a device comprising two or more sieves. In some embodiments of the pharmaceutical composition, sieving the coated API particles comprises sieving the coated API particles to an average particle size of 75 μm or more. In some embodiments of the pharmaceutical composition, sieving the coated API particles comprises sieving the coated API particles to an average particle size of 200 μm or less. In some embodiments of the pharmaceutical composition, the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent. In some embodiments of the pharmaceutical composition, the coating material comprises silica as one or more of a protective coating or flow aid. In some embodiments of the pharmaceutical composition, the one or more deformable components of the coating material comprise a wax. In some embodiments of the pharmaceutical composition, the wax comprises one or more of carnauba wax, candelilla wax, or a synthetic wax. In some embodiments of the pharmaceutical composition, the matrix comprises a matrix-forming agent and a structure-forming agent. In some embodiments of the pharmaceutical composition, the matrix-forming agent comprises one or more of a water-soluble material, a water-dispersible material, a polypeptide, a polysaccharide, a polyvinyl alcohol, a polyvinylpyrrolidone, and an acacia. In some embodiments of the pharmaceutical composition, the matrix-forming agent comprises a polypeptide. In some embodiments of the pharmaceutical composition, the polypeptide comprises gelatin.In some embodiments of the pharmaceutical composition, the structure-forming agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin. In some embodiments of the pharmaceutical composition, the structure-forming agent comprises mannitol.

[0011] In some embodiments, a method of treating a patient is provided, the method comprising administering to the patient a therapeutic amount of the pharmaceutical composition. In some embodiments of the method, the patient is human.

[0012] In some embodiments, a method of preparing a pharmaceutical composition is provided, the method comprising: coating API particles with a first coating material to form coated API particles, the coated material comprising one or more deformable components; applying a mechanical stress to the coated API particles to deform the one or more deformable components of the coating material to form a continuous film layer on the surface of the API particles; coating the coated API particles with silica to form a second coating by applying a mechanical stress to partially embed or embed the silica in the deformable coating; sieving the coated API particles to remove excess coating material; mixing the coated API particles in a matrix solution / suspension to form a pharmaceutical suspension; and administering the pharmaceutical suspension into a mold. In some embodiments of the method, the administration ratio used to combine the coated API particles with the matrix solution / suspension comprises 5-60% w / w of coated API particles to 40-95% w / w of matrix solution / suspension. In some embodiments of the method, the coating ratio used to combine the API particles with the coating material comprises 5-85% w / w coating material and 15-95% w / w uncoated API particles. In some embodiments of the method, the method comprises freezing the administered suspension at a temperature below zero and lyophilizing to form a lyophilized pharmaceutical composition. In some embodiments of the method, the method comprises sieving the uncoated API particles. In some embodiments of the method, sieving the coated API particles comprises passing the coated API particles through a device comprising two or more sieves. In some embodiments of the method, sieving the coated API particles comprises sieving the coated API particles to an average particle size of 75 μm or greater.In some embodiments of the method, sieving the coated API particles comprises sieving the coated API particles to an average particle size of 200 μm or less. In some embodiments of the method, the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent. In some embodiments of the method, the coating material comprises silica as one or more of a protective coating or a flow aid. In some embodiments of the method, one or more deformable components of the coating material comprise a wax.

[0013] In some embodiments of the method, the wax comprises one or more of carnauba wax, candelilla wax, or synthetic wax. In some embodiments of the method, the matrix comprises a matrix-forming agent and a structure-forming agent. In some embodiments of the method, the matrix-forming agent comprises one or more of a water-soluble material, a water-dispersible material, a polypeptide, a polysaccharide, a polyvinyl alcohol, a polyvinylpyrrolidone, and an acacia. In some embodiments of the method, the matrix-forming agent comprises a polypeptide. In some embodiments of the method, the polypeptide comprises gelatin. In some embodiments of the method, the structure-forming agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin. In some embodiments of the method, the structure-forming agent comprises mannitol.

[0014] The invention will now be described, by way of example only, with reference to the accompanying drawings, in which: [Brief description of the drawings]

[0015] [Figure 1A] 1 shows API particles coated with particles of a deformable coating material (i.e., a first coating layer), according to some embodiments. [Figure 1B] 1 shows API particles coated with a continuous film layer (i.e., a first coating layer) of a deformable coating material, according to some embodiments. [Figure 1C]1 shows API particles coated with a continuous film layer of a deformable coating material (i.e., a first coating layer) with silica particles partially embedded and / or embedded on the surface of the first coating layer (i.e., a second coating layer), according to some embodiments. [Diagram 2] 1 shows a scanning electron microscope (SEM) image of uncoated API particles, according to some embodiments. [Diagram 3] 1 shows an SEM image of coated API particles, according to some embodiments. [Figure 4] 1 is a flow chart of a mixing process for preparing coated API particles, according to some embodiments. [Diagram 5] 1A-1P are a series of photomicrographs taken of the sieved coated API of Examples 1-8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Exemplary embodiments of methods for minimizing and / or preventing agglomeration of coating material of coated API particles are described herein. In particular, the methods according to some embodiments include removing excess coating material particles to minimize and / or prevent agglomeration of coating material in the pharmaceutical product. In some embodiments, the methods may include sieving the raw API particles and / or the coated API particles. In particular, the methods provided may include sieving the API particles and / or the coated API particles to remove any undesirable particles, such as excess coating material particles. The sieving process according to the disclosed embodiments may help prevent and / or minimize the possibility of agglomeration of the coating material, which may adversely affect the disintegration time and / or dissolution rate of the final product.

[0017] The methods for minimizing and / or preventing agglomeration of coating material particles according to embodiments described herein may be applied to dry, solvent-free blending processes for coating API particles. Thus, the provided methods are described below in the context of one or more dry, solvent-free blending processes for coating API particles. However, other variations of coating / encapsulation processes may also be used. For example, sugar coating, film coating, other variations of microencapsulation, compression coating, other variations of dry coating, melt coating, dip coating, rotary die coating, electrostatic coating, and / or other suitable types of coating may be used.

[0018] In general, the solvent-free mixing process for coating API particles includes mixing a coating material with the API particles to produce coated API particles. The coated API particles are then mechanically and / or thermally stressed to deform the deformable coating material and create a continuous film surrounding the API particles. The coated API particles are then mixed with a matrix solution / suspension to form a pharmaceutical suspension. The pharmaceutical suspension containing the coated API particles can be dispensed into a preformed mold, such as a blister pack, and further processed to produce a dispensable pharmaceutical composition (e.g., lyophilized, wafer, tablet, etc.).

[0019] However, when the final product is stored, any excess coating material particles that are not bound to the coated API particles may agglomerate. The amount and / or severity of agglomeration may increase over time. Agglomeration of excess coating material may increase the disintegration time and / or decrease the dissolution rate of the pharmaceutical product, which may adversely affect any functional properties of the coating material. Increased disintegration time may also cause unacceptable dispersion and mouthfeel characteristics in vivo.

[0020] Thus, it has been discovered that sieving the coated API particles can remove excess coating material, thereby minimizing the amount of agglomeration of excess coating material during storage. Additionally, some embodiments include optimizing the coating ratio (amount of coating material relative to amount of uncoated API), and optimizing the dosing ratio (amount of coated API particles relative to matrix solution / suspension containing all other inactive ingredients) can also minimize agglomeration of excess coating material particles.

[0021] The embodiments provided herein may be applied to coated API particles produced using dry, solvent-free processes. For example, processes according to some embodiments may be specifically designed to produce pharmaceutical compositions containing bad-tasting APIs that may be administered to pediatric patients, geriatric patients, veterinary patients, and / or other types of patients who may have difficulty swallowing or may be taste-sensitive. In particular, many APIs have undesirable tastes and / or numbing effects that may be problematic for these patients. Thus, some mixing processes according to embodiments described herein include coating the API particles with a taste-masking coating. Such coatings can control the disintegration time and / or dissolution rate of the orodispersible pharmaceutical composition such that the release of the API upon oral administration is delayed or significantly reduced during the first few minutes while in the mouth, but a satisfactory amount of the API is released within 30 minutes of oral administration after swallowing. (For example, a satisfactory amount of the API may be 90% of the amount of API released without the coating). No. 9,107,851 (the '851 patent) is directed to an exemplary dry, solvent-free process for coating pharmaceutical ingredients and is incorporated herein in its entirety.

[0022] However, other variations on coating / encapsulation processes may also be used, such as sugar coating, film coating, other variations on microencapsulation, compression coating, other variations on dry coating, melt coating, dip coating, rotary die coating, electrostatic coating, and / or other suitable types of coating.

[0023] Additionally, certain data provided herein relate to disintegration time. However, disintegration time is inversely proportional to dissolution rate. Thus, the data essentially also provides information regarding dissolution rate. Disintegration time may be measured according to the methodology established by the United States Pharmacopeia (Disintegration 701). In some embodiments, disintegration time may be 2-30 seconds or 5-20 seconds. In some embodiments, disintegration time may be less than 30 seconds, less than 25 seconds, less than 20 seconds, less than 15 seconds, less than 10 seconds, or less than 5 seconds. In some embodiments, disintegration time may be greater than 2 seconds, greater than 5 seconds, greater than 10 seconds, greater than 15 seconds, greater than 20 seconds, or greater than 25 seconds. Similarly, disintegration rate may be tested according to the methodology established by the United States Pharmacopeia (Disintegration 711).

[0024] 1A, 1B, and 1C show different phases of coated API particles according to some embodiments. In some embodiments, the API particles can be combined with one or more coating materials to produce coated API particles. The coating can include materials including water-soluble and / or water-swellable materials as well as water-insoluble materials (described in more detail below).

[0025] For example, FIG. 1A shows an API particle 102 surrounded by particles of a coating material 104. To achieve the coated API particle of FIG. 1A, the combined API particle (i.e., API particle 102) and one or more coating material(s) (i.e., coating material particles 104) may be exposed to mechanical and / or thermal energy to produce an ordered mixture of API particles 102 including discrete layers of coating material particles 104 layering the surface of the API particle 102. The API particle 102 of FIG. 1A is shown with a single layer of discrete particles of the coating material(s). However, the API particle 102 may have two or more discrete layers of coating particles. Additionally, FIG. 2 shows an SEM image of an uncoated API particle.

[0026] FIG. 1B shows API particles 102 surrounded by a continuous deformable film layer 104. Specifically, FIG. 1B shows that all of the coating material particles 104 may be deformable and may deform when subjected to mechanical stress and / or high temperature. Thus, since all coating materials include deformable properties, the coating material 104 of FIG. 1B is a relatively smooth and continuous coating layer after exposure to mechanical and / or thermal energy. In some embodiments, the API particles 102 may have two or more relatively smooth and continuous coating layers. As used herein, a "continuous film" may be a layer surrounding the API particles formed by melting / softening or otherwise decomposing one or more deformable components of individual coating material particles to include a single continuous layer surrounding the API particles. FIG. 3 also provides an SEM image showing coated API particles, according to some embodiments.

[0027] In some embodiments, one or more of the coating materials may not be deformable but may be embedded in the deformable coating layer. Thus, the continuous film may include solid particles of non-deformable material embedded within the deformed coating material. FIG. 1C shows that the continuous film 104 may include one or more solid non-deformable particles 108 of non-deformable material partially embedded and / or embedded within the deformed coating material of the continuous film 104. This continuous film 104 of FIG. 1B or 1C may ensure a coating (e.g., a coating that masks the taste of the API) and delayed API release. In some embodiments, the API particles 102 may have two or more continuous coating layers partially embedded and / or embedded with the non-deformable coating material particles. FIG. 3 also provides an SEM image showing functionally coated API particles according to some embodiments.

[0028] As used herein, the terms "deformable," "deformable component," "deformable component of a coating material," and other related terms refer to one or more components of a water-soluble, water-swellable, and / or water-insoluble material that may degrade when subjected to mechanical stress and / or elevated temperatures.

[0029] The API particles 102 of the coated API particles can be any of a number of APIs. FIG. 2 shows an SEM image of an uncoated API particle, according to some embodiments. As used herein, "active pharmaceutical ingredient" or "API" refers to a pharmaceutical agent that can be used to diagnose, cure, mitigate, treat, or prevent disease. Any API can be used for the purposes of this disclosure. Suitable APIs include, but are not limited to, analgesics and anti-inflammatory agents, antiacids, anthelmintics, antiarrhythmics, antibacterials, anticoagulants, antidepressants, antidiabetics, antidiarrheals, antiepileptics, antifungals, antigouts, antihypertensives, antimalarials, antimigraine, antimuscarinics, antitumor and immunosuppressants, antiprotazoles, antipsychotics, antiemetics, antirheumatics, antithyroids, antivirals, anxiolytics, laxatives, sedatives, hypnotics, and neuroleptics. , beta-blockers, cardiac inotropes, corticosteroids, cough suppressants, cytotoxic agents, decongestants, diuretics, enzymes, anti-Parkinson's drugs, gastrointestinal drugs, histamine receptor antagonists, laxatives, lipid regulating agents, local anesthetics, neuromuscular agents, nitrates and antianginal drugs, nutritional agents, opioid analgesics, oral vaccines, proteins, peptides and recombinant drugs, laxatives, sex hormones and contraceptives, spermicides, and stimulants, and combinations thereof. A list of specific examples of these APIs can be found in U.S. Pat. No. 6,709,669, which is incorporated herein by reference. If present, the API is present in the pharmaceutical formulation in an amount necessary to exhibit the required physiological effect established by clinical studies. One of ordinary skill in the art can easily determine the appropriate amount of API to include in a dosage form made according to the present disclosure.

[0030] In some embodiments, the coated API particles or pharmaceutical compositions may comprise 30.0-90.0% w / w of API. In some embodiments, the coated API particles or pharmaceutical compositions may comprise 40.0-85.0% w / w, 50.0-80.0% w / w, or 70.0-80.0% w / w of API. In some embodiments, the coated API particles or pharmaceutical compositions may comprise more than 40.0% w / w, more than 50.0% w / w, more than 60.0% w / w, more than 65% w / w, more than 70.0% w / w, more than 75.0% w / w, more than 80.0% w / w, or more than 85.0% w / w of API. In some embodiments, the coated API particles or pharmaceutical compositions may comprise less than 90.0% w / w, less than 85.0% w / w, less than 80.0% w / w, less than 75.0% w / w, less than 70.0% w / w, less than 60.0% w / w, less than 50.0% w / w, or less than 40.0% w / w of the API.

[0031] In some embodiments, the raw API particles can be sieved prior to the coating process to achieve a narrower particle size range. For example, the raw API particles may be sieved to remove oversized particles and / or to remove undersized particles. In some embodiments, more than one mesh can be used to remove certain particles. For example, a sieving device may comprise a series of two or more meshes to remove particles of a certain size depending on the size of the mesh(es). The sieve can incorporate a vacuum transfer system to transport the particles through the series of meshes of the device. Additionally, an ultrasonic probe can be incorporated into the sieving device to improve the flow of material during processing and minimize clogging of the meshes.

[0032] In some embodiments, the raw API particles can be sieved using a mesh size of 30 μm to 500 μm, 50 μm to 450 μm, 100 μm to 400 μm, 150 μm to 350 μm, or 200 μm to 300 μm. In some embodiments, the raw API particles can be sieved using a mesh size of less than 500 μm, less than 450 μm, less than 400 μm, less than 350 μm, less than 300 μm, less than 250 μm, less than 200 μm, less than 150, or less than 100 μm. In some embodiments, the raw API particles can be sieved using a mesh size of more than 30 μm, more than 50 μm, more than 100 μm, more than 150 μm, more than 200 μm, more than 250 μm, more than 300 μm, more than 350 μm, or more than 400 μm.

[0033] The coating 104 surrounding the API particles 102 may include materials including water soluble and / or water swellable materials and water insoluble materials. In some embodiments, the coating may directly coat the API particles or may coat API particles that already include one or more coatings. In some embodiments, the ratio of coating material to API particles may be optimized to minimize excess coating material. For example, the coating material may comprise 5-85% w / w, 10-50%, 15-30% of the API and coating material mixture or final pharmaceutical composition. In some embodiments, the coating material may comprise less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, or less than 10% of the API and coating material mixture or final pharmaceutical composition. In some embodiments, the coating material may comprise more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, more than 30%, more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, or more than 75% of the API and coating material mixture or final pharmaceutical composition. In some embodiments, the percentage of coating material may include two or more layers of coating material.

[0034] The water-swellable material of the coating material may be particles with a median particle size of about 0.5 μm to about 20 μm or about 1 μm to about 10 μm. In some embodiments, the water-swellable material may be approximately 10 times smaller than the API to allow for orderly mixing and coating. The water-swellable material may expand upon absorption of water such that the diameter of the water-swellable particles increases by at least about 120-600%. The coating material or pharmaceutical composition may comprise 0-8% w / w or 0.1-0.9% w / w of the water-swellable material. In some embodiments, the coating material or pharmaceutical composition may comprise 0.5-6.0% w / w, 1.0-4.0% w / w, 1.5-3.5% w / w, or 2.0-3.0% w / w of the water-swellable material. In some embodiments, the coating material or pharmaceutical composition may contain less than 8.0% w / w, less than 6.0% w / w, less than 4.0% w / w, less than 2.0% w / w, less than 1.0% w / w, or less than 0.5% w / w of water-swellable material. In some embodiments, the coating material or pharmaceutical composition may contain more than 0.1% w / w, more than 0.5% w / w, more than 1.0% w / w, more than 2.0% w / w, more than 3.0 w / w%, more than 5.0% w / w, or more than 6.0% w / w of water-swellable material. The water-swellable material of the coating material may be deformable under mechanical stress and / or elevated temperature (described in detail below). The water-swellable material may be any one or more of crospovidone, croscarmellose, sodium starch glycolate, or any other suitable disintegrant used in the pharmaceutical industry as an additive or blend made for tableting.

[0035] The water-soluble material of the coating material may be particles having a median particle size of about 0.5 μm to about 20 μm or about 1 μm to about 10 μm. In some embodiments, the water-soluble material may be approximately 10 times smaller than the API to allow for orderly mixing and coating. The water-soluble material may have a water solubility of at least about 50 mg / mL in water at neutral pH and 20° C. Additionally, the water-soluble material may have a water solubility of at least about 3 to 60 μg / m 2The coating material may have an intrinsic dissolution rate of 0.5-25% w / w, 1.0-15% w / w, 1.5-10% w / w, or 2.0-3.0% w / w of the water soluble material. The water soluble material of the coating material may be deformable under mechanical and / or thermal energy. The coating material or pharmaceutical composition may comprise 0-35% w / w of the water soluble material. In some embodiments, the coating material or pharmaceutical composition may comprise 0.5-25% w / w, 1.0-15% w / w, 1.5-10% w / w, or 2.0-3.0% w / w of the water soluble material. In some embodiments, the coating material or pharmaceutical composition may comprise less than 35% w / w, less than 30% w / w, less than 25% w / w, less than 20% w / w, less than 15% w / w, less than 10% w / w, less than 5.0% w / w, less than 4.5% w / w, less than 4.0% w / w, less than 3.5% w / w, less than 3.0% w / w, less than 2.5% w / w, less than 2.0% w / w, less than 1.5% w / w, less than 1.0% w / w, or less than 0.5% w / w of water soluble material. In some embodiments, the coating material or pharmaceutical composition may comprise more than 0.1% w / w, more than 0.5% w / w, more than 1.0% w / w, more than 1.5% w / w, more than 2.0% w / w, more than 2.5% w / w, more than 3.0% w / w, more than 4.0% w / w, more than 5.0% w / w, more than 8.0% w / w, more than 10% w / w, more than 15% w / w, more than 20% w / w, more than 25% w / w, or more than 30% w / w of a water soluble material. The water soluble material may be one or more of sucrose, mannitol, sorbitol, polyvinylpyrrolidone, hydroxypropylcellulose, lactose, poly-(ethylene oxide), and any other suitable micronizable material or polyol.

[0036] The above 3 to 60 μg / m 2 In addition to the intrinsic dissolution rate of about 60-300 μg / m 2The use of water-soluble and / or water-swellable materials with a higher intrinsic dissolution rate of s may be possible. However, API particles with coating materials with higher intrinsic dissolution rates should be dry coated with hydrophobic silica. Dry coated API particles in which the coating comprises water-soluble and / or water-swellable materials with a higher intrinsic dissolution rate may increase the disintegration time of the API, thereby failing to effectively mask the taste of the API. Therefore, dry coating the API particles with silica as a second coating material to slow down the dissolution rate may improve the in vivo taste masking performance of the coating. The coated API may comprise 0.5-35% w / w silica. In some embodiments, the coated ibuprofen or final pharmaceutical composition may comprise 0.5-20% w / w, 0.5-10% w / w, or 0.5-5% w / w hydrophobic fumed silica. In some embodiments, the coated ibuprofen or final pharmaceutical composition can contain more than 0.5% w / w, more than 1.0% w / w, more than 1.5% w / w, more than 2.0% w / w, more than 2.5% w / w, more than 3.0% w / w, more than 4.0% w / w, more than 5.0% w / w, more than 10% w / w, more than 15% w / w, more than 20% w / w, more than 25% w / w, or more than 30% w / w of hydrophobic fumed silica. In some embodiments, the coated ibuprofen or final pharmaceutical composition may contain less than 35% w / w, less than 25% w / w, less than 15% w / w, less than 10% w / w, less than 5.0% w / w, less than 4.0% w / w, less than 3.5% w / w, less than 3.0% w / w, less than 2.5% w / w, less than 2.0% w / w, less than 1.5% w / w, or less than 1.0% w / w of hydrophobic fumed silica.Examples of silica that can be used include, but are not limited to, Aerosil R972 silica (Degussa), CAB-O-SIL EH-5 silica (Cabot), OX-50 silica (Degussa), COSM055 (Catalyst & Chemical Ind. Co. Ltd (Japan)), P-500 hydrophilic silica (Catalyst & Chemical Ind. Co. Ltd (Japan)), and TS5 silica (Cabot). In addition, suitable devices that can be used to dry coat with silica include, but are not limited to, Comil (U3 Quadro Comil of Quadro Pennsylvania, US), LabRAM (Resodyne Minnesota, US), Magnetically Assisted Impact Coater (MAIC, Aveka Minnesota, US), and Fluid Energy Mill (FEM, Qualification Micronizer of Sturtevant Massachusetts US).

[0037] The water-insoluble material of the coating material may also be particles comprising an average particle size smaller than that of the API. For example, the water-insoluble material(s) may comprise an average particle size of about 1-20 μm, about 1-12 μm, about 2-10 μm, about 5-12 μm, or about 5-6 μm. In some embodiments, the water-insoluble material may be approximately 10 times smaller than that of the API to allow for orderly mixing and coating. The water-insoluble material of the coating material may be deformable under mechanical stress and / or elevated temperature. The coating material or pharmaceutical composition may comprise 5-70% w / w, 10-60% w / w, 10-50% w / w, 10-40% w / w, 10-35% w / w, or 15-30% w / w of the water-insoluble material. In some embodiments, the coating material or pharmaceutical composition may comprise more than 5% w / w, more than 10% w / w, more than 15% w / w, more than 20% w / w, more than 25% w / w, more than 30% w / w, more than 35% w / w, or more than 40% w / w of water insoluble material. In some embodiments, the coating material or pharmaceutical composition may comprise less than 70% w / w, less than 60% w / w, less than 50% w / w, less than 45% w / w, less than 40% w / w, less than 35% w / w, or less than 30% w / w of water insoluble material. Examples of suitable water insoluble materials include, but are not limited to, ethyl cellulose, polyethylene, polypropylene, polytetrafluoroethylene, carnauba wax, candela wax, castor wax, polyamide wax, and / or synthetic waxes.

[0038] In some embodiments, mechanical and / or thermal energy can be used to deform one or more water-insoluble, water-swellable, and / or water-insoluble materials. For example, a PharmaRAM II acoustic mixer, a RAM5 Pharma mixer, or a RAM55 Pharma mixer (Resodyn Mixers) can be used to apply mechanical stress to the functionally coated API particles. The coated API particles can be exposed to up to 100 times the force of gravity (100G acceleration) during this acoustic mixing process. These high forces cause particle-particle collisions that generate energy in the form of heat, which can be used to deform one or more water-insoluble, water-swellable, and / or water-insoluble materials on the API.

[0039] In this step, mixing the deformable coating material with the API particles produces API particles surrounded or coated with coating material particles, as shown in Figure 1A. Figure 1A shows API particles 102 coated with individual coating material particles 104 to create coated API particles. In some embodiments, the coated API can be further coated with a second non-coating material, as shown in Figure 1C. Figure 1C shows API particles 102 coated with a layer of deformable coating material 104 and partially embedded with particles of a second coating material 108.

[0040] However, the above coating process may also produce "loose" or "free" coating material particles. Figure 2 is an SEM image of an uncoated API particle. Figure 3 is an SEM image of a coated API particle 312. However, the "loose" or "free" coating material particles 314 are not bound to the coated API particle 312.

[0041] Once the API particles are coated with a coating material to produce coated API particles, the coated API particles can be sieved to remove excess coating material and residual fine API particles that are uncoated, partially coated, or coated. The excess coating material may include any coating material particles that are not bound to the coated API particles. Upon storage of the final pharmaceutical composition (i.e., product), any excess coating material may agglomerate. For example, fusion may occur between the excess coating particles and the coating particles already bound to the API particles, preventing the ingress of media that would otherwise aid in the disintegration of the unit or tablet, or the dissolution of the coated API particles. Thus, agglomeration of excess coating material may cause an increase in disintegration time and / or a decrease in dissolution rate upon administration.

[0042] However, it has been determined that a method of sieving excess coating material from coated API particles can minimize agglomeration of the coating material and maintain the initial disintegration time and / or dissolution rate of the final product. The sieving process can be either batch or continuous. Furthermore, this sieving process can be performed in addition to or instead of the sieving process performed on the raw API particles described above. In some embodiments, the parameters of the sieving process can be different between uncoated raw API particles and coated API particles.

[0043] In some embodiments, the coated API particles can be sieved to remove coating material particles having an average particle size less than the average particle size of the desired coated API particles. In some embodiments, more than one mesh can be used to remove certain particles. For example, a sieving device can include a series of two or more meshes to remove particles of a certain size depending on the size of the mesh(es). The sieve can incorporate a vacuum transfer system to deliver particles to the series of meshes of the device. Additionally, an ultrasonic probe can be incorporated into the sieving device to improve the flow of the material during processing and minimize clogging of the meshes. Flow aids (e.g., silica) may be included to facilitate movement through the sieve. For example, the coating material used to coat the API particles may include a flow aid. Conversely, raw API material may be non-cohesive and not require the assistance of a flow aid during sieving. The sieving process may be a batch or continuous process.

[0044] In some embodiments, the raw API particles can be sieved using a mesh size of 30 μm to 500 μm, 50 μm to 450 μm, 100 μm to 400 μm, 150 μm to 350 μm, or 200 μm to 300 μm. In some embodiments, the raw API particles can be sieved using a mesh size of less than 500 μm, less than 450 μm, less than 400 μm, less than 350 μm, less than 300 μm, less than 250 μm, less than 200 μm, less than 150, or less than 100 μm. In some embodiments, the raw API particles can be sieved using a mesh size of more than 30 μm, more than 50 μm, more than 100 μm, more than 150 μm, more than 200 μm, more than 250 μm, more than 300 μm, more than 350 μm, or more than 400 μm.

[0045] Once sieved, the coated API particles can be mixed into a matrix solution / suspension to form a pharmaceutical suspension and dosed by weight into pockets of preformed blister packs to form aliquots of pharmaceutical suspension. Once dosed, the blister packs containing the aliquot pharmaceutical suspension are frozen under sub-zero conditions. The frozen aliquots of pharmaceutical suspension are kept in a frozen state until ready for lyophilization, during which the solvent of the pharmaceutical suspension is removed to form the pharmaceutical composition.

[0046] The matrix solution / suspension may include a matrix former, a structure former, and a solvent. For example, the matrix former may include any water-soluble or water-dispersible material that is pharmacologically acceptable or inert to the functionally coated API particles. In some embodiments, the matrix former may be a polypeptide, such as gelatin. Gelatin may be at least partially hydrolyzed (by heating in water). Other suitable matrix former materials include, but are not limited to, hydrolyzed dextran, dextrin, and polysaccharides, such as alginate, polyvinyl alcohol, polyvinylpyrrolidone, and / or acacia. In some embodiments, the amount of matrix in the final pharmaceutical composition (e.g., orally disintegrating tablet) may be 1-30% w / w. In some embodiments, the amount of matrix may be less than 30% w / w, less than 25% w / w, less than 20% w / w, less than 15% w / w, less than 10% w / w, less than 5% w / w, or less than 3% w / w. In some embodiments, the amount of matrix may be greater than 1% w / w, greater than 3% w / w, greater than 5% w / w, greater than 10% w / w, greater than 15% w / w, greater than 20% w / w, or greater than 25% w / w.

[0047] In some embodiments, the amount of matrix former in the matrix solution / suspension or pharmaceutical suspension may be about 0.1-10% w / w. In some embodiments, the amount of matrix former in the matrix solution / suspension or pharmaceutical suspension may comprise 1.0-8.0% w / w or 2.0-5.0% w / w. In some embodiments, the amount of matrix former in the matrix solution / suspension or pharmaceutical suspension may comprise more than 0.1% w / w, more than 0.5% w / w, more than 1.0% w / w, more than 2.0% w / w, more than 3.0% w / w, more than 4.0% w / w, more than 4.5% w / w, more than 5.0% w / w, or more than 8.0% w / w. In some embodiments, the amount of matrix forming agent in the matrix solution / suspension or pharmaceutical suspension may include less than 10% w / w, less than 8.0% w / w, less than 6.0% w / w, less than 5.0% w / w, less than 4.0% w / w, less than 3.0% w / w, less than 2.5% w / w, less than 2.0% w / w, less than 1.5% w / w, or less than 1.0% w / w. In some embodiments, the amount of matrix forming agent in the pharmaceutical composition may be about 3-15% w / w, about 4-10% w / w, or about 4-7% w / w. In some embodiments, the amount of matrix forming agent in the pharmaceutical composition may comprise greater than 0.1% w / w, greater than 0.5% w / w, greater than 1.0% w / w, greater than 2.0% w / w, greater than 3.0% w / w, greater than 4.0% w / w, greater than 5.0% w / w, greater than 6.0% w / w, greater than 7.0% w / w, greater than 8.0% w / w, greater than 9.0% w / w, greater than 10.0% w / w, greater than 11.0% w / w, greater than 12.0% w / w, greater than 13.0% w / w, or greater than 14.0% w / w. In some embodiments, the amount of matrix forming agent in the pharmaceutical composition may comprise less than 15% w / w, less than 14.0% w / w, less than 13.0% w / w, less than 12.0% w / w, less than 10.0% w / w, less than 9.0% w / w, less than 8% w / w, less than 7% w / w, less than 6% w / w, less than 5% w / w, or less than 4.0% w / w.

[0048] The structure-forming agent, or bulking agent, of the matrix solution / suspension may include a sugar. For example, suitable structure-forming agents include, but are not limited to, mannitol, dextrose, lactose, galactose, glycine, cyclodextrin, or combinations thereof. Structure-forming agents can be used as bulking agents in lyophilization because they crystallize to provide structural robustness to the lyophilized dosage form. In some embodiments, the amount of structure-forming agent in the matrix solution / suspension may be about 0.1-10% w / w. In some embodiments, the amount of structure-forming agent in the matrix solution / suspension or pharmaceutical suspension may include 1.0-8.0% w / w or 2.0-5.0% w / w. In some embodiments, the amount of structure-forming agent in the matrix solution / suspension or pharmaceutical suspension may comprise more than 0.1% w / w, more than 0.5% w / w, more than 1.0% w / w, more than 2.0% w / w, more than 3.0% w / w, more than 4.0% w / w, more than 4.5% w / w, more than 5.0% w / w, or more than 8.0% w / w. In some embodiments, the amount of structure-forming agent in the matrix solution / suspension or pharmaceutical suspension may comprise less than 10% w / w, less than 8.0% w / w, less than 6.0% w / w, less than 5.0% w / w, less than 4.0% w / w, less than 3.0% w / w, less than 2.5% w / w, less than 2.0% w / w, less than 1.5% w / w, or less than 1.0% w / w. In some embodiments, the amount of structure-forming agent in the pharmaceutical composition may be about 3-15% w / w, about 4-10% w / w, or about 4-7% w / w. In some embodiments, the amount of structure-forming agent in the pharmaceutical composition may include greater than 0.1% w / w, greater than 0.5% w / w, greater than 1.0% w / w, greater than 2.0% w / w, greater than 3.0% w / w, greater than 4.0% w / w, greater than 5.0% w / w, greater than 6.0% w / w, greater than 7.0% w / w, greater than 8.0% w / w, greater than 9.0% w / w, greater than 10.0% w / w, greater than 11.0% w / w, greater than 12.0% w / w, greater than 13.0% w / w, or greater than 14.0% w / w. In some embodiments, the amount of structure forming agent in the pharmaceutical composition may comprise less than 15% w / w, less than 14.0% w / w, less than 13.0% w / w, less than 12.0% w / w, less than 10.0% w / w, less than 9.0% w / w, less than 8% w / w, less than 7% w / w, less than 6% w / w, less than 5% w / w, or less than 4.0% w / w.

[0049] The solvent for the matrix solution / suspension and pharmaceutical suspension may be water, while the suspension may include a co-solvent. In some embodiments, the solvent may be ethanol, alcohol, isopropanol, other lower alkanols, water (e.g., purified water), or a combination thereof. For example, a suitable solvent and / or co-solvent may be an alcohol, such as tert-butyl alcohol. In some embodiments, the remaining balance of the pharmaceutical suspension is solvent (i.e., QS100%).

[0050] The matrix solution / suspension and pharmaceutical suspension may also contain additional pharma- ceutically acceptable agents or excipients. Such additional pharma-ceutically acceptable agents or excipients include, but are not limited to, sugars, inorganic salts such as sodium chloride and aluminum silicate, modified starches, preservatives, antioxidants, viscosity enhancers, colorants, flavoring agents, pH adjusters, sweeteners, taste masking agents, and combinations thereof. Suitable colorants may include red, black, and yellow iron oxides, and FD&C dyes such as FD&C Blue No. 2 and FD&C Red No. 40, and combinations thereof. Suitable flavoring agents may include mint, raspberry, licorice, orange, lemon, grapefruit, caramel, vanilla, cherry, and grape flavors, and combinations thereof. Suitable pH adjusters may include citric acid, tartaric acid, phosphoric acid, hydrochloric acid, maleic acid, sodium hydroxide (e.g., 3% w / w sodium hydroxide solution), and combinations thereof. Suitable sweeteners may include aspartame, acesulfame K and thaumatin, and combinations thereof.Suitable taste-masking agents may include sodium bicarbonate, ion exchange resins, cyclodextrin-containing compounds, adsorbents or microencapsulated active agents, and combinations thereof.Those skilled in the art can easily determine the appropriate amounts of these various additional excipients, as needed.

[0051] 4 provides a flow chart according to some embodiments of a mixing process for preparing a pharmaceutical composition described herein. In step 402, API particles are combined with one or more coating material(s) and the combination is exposed to mechanical and / or thermal energy to produce an ordered mixture of API particles comprising a discrete layer of one or more coating material(s) (i.e., API particles comprising a first coating layer). For example, FIG. 1A shows an API particle comprising a discrete layer of coating material particles.

[0052] In step 404, mechanical and / or thermal energy can be applied to the coated API particles to transform one or more deformable components of the coating material onto the surface of the API particles. This process step can form API particles that include a continuous film surrounding the API particles, as shown in Figures 1B, 1C, and / or 3.

[0053] In step 406, the coated API particles are combined with silica to form coated API particles including at least a first coating of a functional coating material and a second coating of silica. In some embodiments, mechanical and / or thermal energy can be applied to cause the silica particles to adhere to and / or become embedded within the first coating of the coated API particles.

[0054] In step 408, the coated API particles are sieved to remove any excess coating material, as discussed in detail above. For example, Figure 3 shows an SEM image of coated API particles 312 and excess coating material 314.

[0055] In step 410, the sieved coated API particles are mixed into a matrix solution / suspension to form a pharmaceutical suspension for administration into a preformed mold. In some embodiments, the pharmaceutical suspension may be administered into a blister pack and lyophilized to remove the solvent to form a pharmaceutical composition and sealed in the blister pack for protection. This suspension and administration process is covered in detail in GB1548022, US4371516, US4305502, GB211423, and US4758598, each of which is incorporated herein in its entirety.

[0056] The coating ratio (i.e., amount of coating material relative to amount of uncoated API) can be optimized to minimize and / or prevent excessive agglomeration of coating material. For example, in some embodiments, the coating ratio can range from 5-85% or 10-150% w / w coating material to 15-95% or 50-90% w / w uncoated API. In some embodiments, the amount of coating material can be less than 80% w / w, less than 70% w / w, less than 60% w / w, less than 50% w / w, less than 40% w / w, less than 30% w / w, less than 20% w / w, or less than 10% w / w. In some embodiments, the amount of coating material can be more than 5% w / w, more than 10% w / w, more than 20% w / w, more than 30% w / w, more than 40% w / w, more than 50% w / w, more than 60% w / w, or more than 70% w / w. In some embodiments, the amount of uncoated API can be less than 95% w / w, less than 85% w / w, less than 75% w / w, less than 65% w / w, less than 55% w / w, less than 45% w / w, less than 35% w / w, or less than 25% w / w. In some embodiments, the amount of uncoated API can be more than 20% w / w, more than 30% w / w, more than 40% w / w, more than 50% w / w, more than 60% w / w, more than 70% w / w, more than 80% w / w, or more than 90% w / w.

[0057] The dosing ratio (i.e., the amount of coated API relative to the amount of matrix solution / suspension including all inactive ingredients) may be optimized to minimize and / or prevent excessive agglomeration of coating material. For example, in some embodiments, the dosing ratio may range from 5-60% w / w of coated API to 40-95% w / w of matrix solution / suspension. In some embodiments, the dosing ratio may include less than 60% w / w, less than 50% w / w, less than 40% w / w, less than 30% w / w, less than 20% w / w, or less than 10% w / w of coated API. In some embodiments, the dosing ratio may include more than 5% w / w, more than 10% w / w, more than 20% w / w, more than 30% w / w, more than 40% w / w, or more than 50% w / w of coated API. In some embodiments, the dosing ratio may comprise less than 95% w / w, less than 90% w / w, less than 80% w / w, less than 70% w / w, less than 60% w / w, or less than 50% w / w of the matrix solution / suspension. In some embodiments, the dosing ratio may comprise more than 40% w / w, more than 50% w / w, more than 60% w / w, more than 70% w / w, more than 80% w / w, or more than 90% w / w of the matrix solution / suspension. EXAMPLES

[0058] Several tests were performed to evaluate the effectiveness of removing excess coating material from coated API particles by sieving and to optimize the coating ratio and dosing ratio. The disintegration time of pharmaceutical compositions containing various coated API particles was measured under various conditions to study the effect of sieving excess coating material. It can be reasonably assumed that removing excess coating material can minimize the agglomeration of the coating material. Optimizing the coating and dosing ratio can also help to minimize the agglomeration of the coating material. In turn, minimizing the amount of agglomeration can help maintain the desired disintegration time and / or dissolution rate of the pharmaceutical composition and coated API particles. Therefore, disintegration time is used as a metric to evaluate the amount of agglomeration in the following examples. In some embodiments, accelerated disintegration data at 50° C. can indicate the presence of excess coating material that has not been sieved.

[0059] Additionally, coating ratio and dosing ratio information is provided for the following examples. Coating ratio refers to the amount of coating material relative to the amount of uncoated API. Dosing ratio refers to the amount of coated API relative to the matrix solution / suspension containing all inactive ingredients.

[0060] Example 1: Ibuprofen was coated with carnauba wax at a coating ratio of 26:74. A dose ratio of 40:60 was used to produce freeze-dried tablets. Four separate batches of tablets were tested (batches 1-3 over 2 months and batch 4 over 6 months). These batches of tablets were tested at ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH, respectively, and sampled at 1 and 2 months for batches 1, 2, and 3. Additionally, each batch was exposed to stress conditions of 50°C to provide accelerated data at both 2 and 4 weeks for each study. Table 1 below provides disintegration time data for batches 1-3 of the 2-month study of coated ibuprofen. [Table 1]

[0061] The coated API for batch 2 was poorly sieved after API coating. Microscopic examination of the sieved coated API (Figure 5B) indicated the presence of an excessive amount of unbound coating material. It also indicated that the API particles were poorly coated. As shown in the last column of Table 1, this batch exhibited a significantly longer disintegration time at 40°C / 75% RH stability test conditions after 2 months. (Initial disintegration time was less than 2 seconds, and disintegration time at 2 months was nearly 15 seconds). Therefore, this result supports the hypothesis that the presence of an excessive amount of unbound coating material in the drug product causes an extension of disintegration time over time (as the drug product ages) due to aggregation of the unbound coating material during storage.

[0062] Conversely, the coated API for batch 3 was thoroughly sieved after API coating. Microscopic examination of the sieved coated API (Figure 5C) showed that the API particles were thoroughly coated due to the absence of unbound coating material. The disintegration times of the samples from this batch did not change significantly over the two-month period for any of the ICH stability conditions. (Disintegration times throughout the two-month study ranged from approximately 1 second to approximately 3 seconds). This supports the hypothesis that minimizing the presence of excess unbound coating material, for example by sieving, helps prevent agglomeration of the coating material in the drug product, especially when stored at elevated temperatures over time.

[0063] The coated API for batch 1 was sieved after API coating. Batch 1 showed similar disintegration times of less than 2 seconds compared to batches 2 and 3 for the initial time data points. However, after 2 months at 40C / 75%RH stability test conditions, the disintegration time increased to approximately 7 seconds or less. When stored at 50°C for 4 weeks, the disintegration time increased to approximately 10 seconds or less. This suggests that the sieving process of this batch did not adequately remove excess coating material, thus suggesting the presence of residual unbound coating material. Batch 2 experienced even more unbound coating material and a greater degree of agglomeration upon storage than that of batch 1. Microscopic examination of the sieved coated API (Figure 5A) showed that the API particles were reasonably well coated in the presence of residual amounts of unbound coating material.

[0064] Table 2 below shows the disintegration time data for a six month study of the coated ibuprofen API (ie, Batch 4). [Table 2]

[0065] The coated API for Batch 4 was sieved after API coating. Batch 4 in Table 2 showed little change in disintegration time over the 6 month study period. The initial disintegration time for Batch 4 was approximately 5 seconds, with the final disintegration time for the 25°C / 60% RH sample being approximately 2 seconds, the 30°C / 65% RH sample being approximately 2 seconds, and the 40°C / 75% RH sample being approximately 2 seconds. However, an increase was observed upon storage at 50°C. As no increase was observed for tablets stored at temperatures below 40°C, this suggests that sieving removed most of the excess unbound coating material, but provided sufficient residual amounts to agglomerate when the tablets were placed at 50°C. Microscopic examination (Figure 5D) showed that the sieved coated API showed that the API particles were reasonably well coated in the presence of residual amounts of unbound coating material.

[0066] Example 2: Ibuprofen was coated with Sasol (synthetic) wax with a theoretical coating ratio of 26:74. The coated API was sieved after coating. Lyophilized tablets were produced using a 40:60 dose ratio and tested over a two month period. The ibuprofen API strength was 200mg. Each batch was tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Additionally, samples were exposed to stress conditions at 50°C to provide accelerated data at weeks 2 and 4 during the study. Table 3 below provides disintegration time data for the two month study of coated ibuprofen with a 40:60 dose ratio. Microscopic examination of the sieved coated API (Figure 5E) showed that the API particles were reasonably well coated with a small amount of unbound coating material present. [Table 3]

[0067] Batch 5 in Table 3 shows no substantial change in disintegration time during the 2 month study or at the accelerated condition at 50°C. Specifically, the initial disintegration time for Batch 5 was approximately 3 seconds, and the disintegration time at 2 months was approximately 4 seconds for all three ICH stability conditions (25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH). The disintegration time at 50°C accelerated condition at 2 weeks was approximately 3 seconds, and the disintegration time at 4 weeks was approximately 4 seconds. Based on the 50°C data, there may be a small residual amount of excess unbound coating material. If so, this small amount of excess unbound coating material does not cause a significant amount of clumping during storage, as the disintegration time does not increase significantly, if at all. This compares well with Batch 3 in Example 1, which used a different wax. These two examples demonstrate that clumping of coating material in a pharmaceutical product during storage can be minimized or prevented, especially at higher temperatures and during long storage periods, if excess unbound coating material is efficiently removed by sieving.

[0068] Example 3: Ibuprofen was coated with Sasol (synthetic) wax with a theoretical coating ratio of 26:74. After coating, the coated API was then sieved. A 50:50 dose ratio was used to produce freeze-dried tablets and tested over a 3-month period. The ibuprofen strength was 200mg. As with Examples 1 and 2 above, each batch was tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Samples were also exposed to stress conditions at 50°C to provide accelerated data at 2 and 4 weeks during each study. Table 4 below provides data for a 3-month study of ibuprofen coated with 50:50 Sasol wax. Microscopic examination of the sieved coated API from batch 6 (Figure 5F) showed that the API particles were well coated with some unbound coating material present. [Table 4]

[0069] Neither Batch 6 nor Batch 7 showed any significant change in disintegration time over the course of the three month study. Specifically, the initial disintegration time for Batch 6 samples was approximately 1 second, and the final three months at each of the three ICH stability conditions (25° C. / 60% RH, 30° C. / 65% RH, and 40° C. / 75% RH) were approximately 2 seconds. The disintegration times for Batch 6 at both the 2 week and 4 week accelerated 50° C. conditions were approximately 2 seconds.

[0070] The initial disintegration time for the batch 7 sample was approximately 2 seconds, and the final 3 month disintegration times at 25°C / 60% and 30°C / 65% ICH stability conditions were approximately 2 seconds. The final 3 month disintegration time at 40°C / 75% ICH stability conditions was approximately 3 seconds. The disintegration times at both the 2 week and 4 week accelerated 50°C conditions were approximately 5 seconds. The high coating ratio of 50:50 may increase the amount of excess unbound coating material if left unsieved. Although both batches used a higher dosing ratio of 50:50, which implies a high loading of the coated API and any excess unbound coating material, these data inferred that the sieving process of the coated API was effective in removing excess unbound coating material to minimize agglomeration. Example 4: Paracetamol (APAP) was coated with carnauba wax at a theoretical coating ratio of 26:74. The batches were manually sieved. Dosage ratios of 50:50 and 40:60 were used to produce freeze-dried tablets. APAP strength was 325mg. Each batch was tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Samples were also exposed to stress conditions at 50°C to provide accelerated data at 2 weeks during each study. Table 5 below provides data for a one-month study of APAP coated with carnauba wax. As shown below, all batches showed a significant increase in disintegration time at one month at 40°C / 75% RH stability conditions. Microscopic examination of the manually sieved coated API showed poor to moderate API particle coating for batch 8 (Figure 5G) and very poor coating for batches 9 and 10 (Figures 5H and 5I). The poor coating is due to the presence of excess unbound coating material as a result of poor sieving performed manually instead of using a vibrating sieve. [Table 5]

[0071] The initial disintegration time of each batch of samples was approximately 2-4 seconds. None of the batches showed significant change in disintegration time at 25°C / 60% RH and 30°C / 65% RH stability conditions when tested after one month. The disintegration times of all three batches at the two week accelerated 50°C condition were greater than 2 minutes. As mentioned above, all three batches also showed a significant increase in disintegration time (greater than 2 minutes) after one month at 40°C / 75% RH stability conditions. This may be explained by the presence of excess unbound wax coating material that aggregated during storage of the drug product.

[0072] Example 5: APAP was coated with Sasol (synthetic) wax with a theoretical coating ratio of 26:74 and sieved. 50:50 dosing ratio to produce a freeze-dried tablet. APAP strength was 325mg. Testing conditions were identical to those described in Example 4 above. That is, batches were tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Samples were exposed to stress conditions at 50°C to provide accelerated data at 2 weeks. Table 6 below provides data for a one-month study of APAP coated with Sasol (synthetic) wax. As shown below, batch 11 did not show significant changes in disintegration time for any of the test conditions. Microscopic examination of the sieved coated API (Figure 5J) shows that the API particles are reasonably well coated in the presence of non-bound coating material. [Table 6]

[0073] The initial disintegration time for batch 11 was less than 2 seconds. There was little change in disintegration time when tested at one month for all three stability conditions (25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH). The disintegration time at the two week accelerated 50°C condition was greater than 2 minutes. Since no increase was seen in tablets stored at temperatures below 40°C, this suggests that sieving removed most of the unbound excess coating material but left enough residual material to clump when the tablets were placed at 50°C. Sasol wax also has a higher melting / softening point that can occur at higher storage temperatures (e.g., 50°C).

[0074] Example 6: APAP was coated with Sasol (synthetic) wax with a theoretical coating ratio of 24:76 and sieved. A 50:50 dosing ratio was used to produce freeze-dried tablets and studied over 3 and 6 months. (Batch 11 of Example 5 was extended from 1 month to 3 months for this example). APAP strength for all samples was 325 mg. Each batch was tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Additionally, samples from each batch were exposed to stress conditions at 50°C to provide accelerated data at the second week of each study. Table 7 below provides disintegration time data for coated APAP with a 50:50 dosing ratio for the 3 month study (Batch 11) and the 6 month study (Batch 12). Similar to Batch 11, microscopic examination of the sieved coated API of Batch 12 (Figure 5K) showed that the API particles were reasonably well coated with unbound coating material. [Table 7]

[0075] Batch 12 showed no substantial change during the 3-month study at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Specifically, the initial disintegration time was approximately 2 seconds, the final 3-month disintegration time for the 25°C / 60% RH sample was approximately 4 seconds, and the final disintegration time for the 30°C / 65% RH and 40°C / 75% RH samples was approximately 3 seconds. However, the 2-week 50°C accelerated data showed a significant change in disintegration time (>2 minutes). As described in Example 5, Sasol wax has a higher melting / softening temperature. This relatively high melting / softening point supports the microscopic observation that excess unbound coating material aggregated when stored at 50°C, but not to the same extent when the tablets were stored at 40°C / 75% RH, as no increase was observed in tablets stored at temperatures below 40°C.

[0076] Batch 13 behaved similarly to Batch 12, showing no substantial change in disintegration time over the course of the six month study. The initial disintegration time for the Batch 13 samples was approximately 1 second. The final disintegration times at six months for the 25° C. / 60% RH and 30° C. / 65% RH samples were approximately 2 seconds, and the final disintegration time at six months for the 40° C. / 75% RH sample was approximately 3 seconds. Additionally, the two week 50° C. accelerated data resulted in disintegration times of greater than two minutes.

[0077] Comparing the observations of batches 12 and 13 with batches 5-7 of examples 3 and 4, both examples showed similar disintegration times for samples stored at 25°C / 60%, 30°C / 65%, and 40°C / 75%. However, differences in disintegration times were observed for samples stored at 50°C. After storing the tablets at 50°C for two weeks, disintegration times were greater than 2 minutes for batches 12 and 13. In contrast, disintegration times were between 2 and 4 seconds. This difference suggests that there was less excess unbound coating material in batches 5-7 when compared to batches 11-12. This difference did not cause clumping of the coating material at the lower storage temperatures of 25°C, 30°C, and 40°C, but is enough to make a difference at 50°C due to the higher melting / softening temperature of Sasol wax.

[0078] Example 7: APAP was coated with Sasol (synthetic) wax with a theoretical coating ratio of 26:74 and sieved. A dosing ratio of 40:60 to produce freeze-dried tablets and study over a 2 month period. APAP strength for all samples was 325mg. Samples were tested at ICH stability conditions of 25°C / 60% RH, 30°C / 65% RH, and 40°C / 75% RH. Additionally, samples from each batch were exposed to stress conditions at 50°C to provide accelerated data at weeks 2 and 4 during the study. Table 8 below provides the disintegration times for this study. Similar to batches 12 and 13, microscopic examination of the sieved coated API of batch 14 (Figure 5L) showed that the API particles were reasonably well coated with residual amounts of unbound coating material. [Table 8]

[0079] Batch 14 showed no change in disintegration time or accelerated data over the course of the two month study. The initial disintegration time for the batch 14 sample was approximately 3 seconds. The final two month disintegration times at all three ICH stability conditions were approximately 2 seconds. Additionally, the two week 50°C accelerated data disintegration time was approximately 3 seconds and the four week 50°C accelerated data disintegration time was approximately 2 seconds. Comparing this to batch 11 of Example 5 and batch 12 of Example 6, which used a 50:50 dosing ratio, this example shows that by reducing the dosing ratio to 40:60, the amount of excess unbound coating material remaining in the sieved coated API can be reduced and excess wax agglomeration can be minimized, especially during storage at higher temperatures over time.

[0080] Example 8: Ibuprofen was coated with carnauba wax at theoretical coating ratios of 22.5:77.5 and 30:70. A 30:70 dose ratio was used to produce freeze-dried tablets that were studied over a two month period. The ibuprofen strength is 200 mg. The batches were stored in an oven at 40° C. The tablets were tested for disintegration time at initial, 25 days, and two months. Table 9 below provides the disintegration times for the study. Microscopic examination of the unsieved coated API (FIGS. 5M and 5O) and the sieved coated API (FIGS. 5N and 5P). The API particles were well coated. There is no unbound coating material in the sieved samples. [Table 9]

[0081] Batches 15-18 show that the disintegration time of tablets stored at 40°C using a 30:70 dosing ratio for either unsieved (batches 15 and 17) or sieved (batches 16 and 18) coated API does not increase over time. This supports the hypothesis that by reducing the dosing ratio, such as 30:70, the amount of excess unbound wax is sufficiently reduced to a level that can minimize clumping of excess unbound material when stored at higher temperatures over time.

[0082] A general summary of the results from the above examples is presented in Table 10. [Table 10-1] [Table 10-2]

[0083] The foregoing description has been set forth in terms of specific embodiments for purposes of illustration. However, the illustrative discussion above is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in light of the above teachings. The embodiments were chosen and described in order to best explain the principles of the techniques and their practical application. In order to enable those skilled in the art to optimally utilize the techniques and various embodiments, with various modifications suited to the particular use contemplated.

[0084] Although the present disclosure and embodiments have been fully described with reference to the accompanying drawings, it should be noted that various changes and modifications will be apparent to those skilled in the art, and such changes and modifications should be understood to be included within the scope of the present disclosure and embodiments as defined by the appended claims.

Claims

1. 1. A pharmaceutical composition comprising: 65-85% w / w of API particles; a coating material encapsulating said API particles at 15-30% w / w; and a matrix surrounding said coated API particles of 3-15% w / w, wherein said pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 25° C. and at least 60% relative humidity for at least 6 months.

2. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 30°C and at least 65% relative humidity for at least 6 months.

3. 3. The pharmaceutical composition of claim 1 or claim 2, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 40° C. and at least 75% relative humidity for at least 6 months.

4. 4. The pharmaceutical composition of any one of claims 1 to 3, wherein the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the coating material comprises silica as one or more of a protective coating or a flow aid.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein the coating material comprises a wax.

7. 7. The pharmaceutical composition of any one of claims 1 to 6, wherein the coating material comprises one or more of carnauba wax, candelilla wax, or synthetic wax.

8. 8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the coating ratio used to combine said API particles with said coating material comprises 5-85% w / w of coating material and 15-95% w / w of uncoated API particles.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the matrix comprises a matrix-forming agent and a structure-forming agent.

10. 10. The pharmaceutical composition of claim 9, wherein the matrix forming agent comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.

11. The pharmaceutical composition of claim 9 or 10, wherein the matrix-forming agent comprises a polypeptide.

12. The pharmaceutical composition of claim 10 or 11, wherein the polypeptide comprises gelatin.

13. 13. The pharmaceutical composition of any one of claims 8 to 12, wherein the structure-forming agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.

14. 14. The pharmaceutical composition of any one of claims 8 to 13, wherein the structuring agent comprises mannitol.

15. 1. A pharmaceutical composition comprising: coating the API particles with a coating material to form coated API particles, said coating material comprising one or more deformable components; applying a mechanical stress to the coated API particles to deform the one or more deformable components; coating said coated API particles with silica; applying a mechanical stress to at least one of adhere, partially embed or embed said silica on said coated API particles; sieving the coated API particles to remove excess coating material, wherein the excess coating material comprises coating material that is not bound to the coated API particles; mixing the coated API particles into a matrix solution / suspension to form a pharmaceutical suspension; and administering said pharmaceutical suspension into a mold, wherein said pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 25° C. and at least 60% relative humidity for at least six months.

16. 16. The pharmaceutical composition according to claim 15, wherein the dosage ratio used for combining said coated API particles with said matrix solution / suspension comprises 5-60% w / w of coated API particles and 40-95% w / w of matrix solution / suspension.

17. 17. The pharmaceutical composition according to claim 15 or 16, wherein the coating ratio used to combine the API particles with the coating material comprises 5-85% w / w of coating material and 15-95% w / w of uncoated API particles.

18. 18. The pharmaceutical composition of any one of claims 15 to 17, comprising freezing the administered suspension under sub-zero conditions and lyophilizing to form a lyophilized pharmaceutical composition.

19. 19. The pharmaceutical composition of any one of claims 15 to 18, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 30°C and at least 65% relative humidity for at least 6 months.

20. 20. The pharmaceutical composition of any one of claims 15 to 19, wherein the pharmaceutical composition comprises a disintegration time of less than 10 seconds under storage conditions of at least 40°C and at least 75% relative humidity for at least 6 months.

21. 21. The pharmaceutical composition according to any one of claims 15 to 20, comprising 65-85% w / w of API particles.

22. A pharmaceutical composition according to any one of claims 15 to 21, comprising 15 to 30% w / w of a coating material.

23. A pharmaceutical composition according to any one of claims 15 to 22, comprising 3 to 15% w / w matrix.

24. The pharmaceutical composition according to any one of claims 15 to 23, comprising sieving the uncoated API particles.

25. The pharmaceutical composition according to any one of claims 15 to 18, wherein sieving the coated API particles comprises passing the coated API particles through a device comprising two or more sieves.

26. The pharmaceutical composition according to any one of claims 15 to 25, wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 75 μm or greater.

27. The pharmaceutical composition according to any one of claims 15 to 26, wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 200 μm or less.

28. 28. The pharmaceutical composition of any one of claims 15-27, wherein the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent.

29. The pharmaceutical composition of any one of claims 15 to 28, wherein the coating material comprises silica as one or more of a protective coating or a flow aid.

30. The pharmaceutical composition of any one of claims 15 to 29, wherein the one or more deformable components of the coating material comprise a wax.

31. 31. The pharmaceutical composition of any one of claims 15 to 30, wherein the wax comprises one or more of carnauba wax, candelilla wax, or a synthetic wax.

32. The pharmaceutical composition according to any one of claims 15 to 31, wherein the matrix solution / suspension comprises a matrix-forming agent and a structure-forming agent.

33. 33. The pharmaceutical composition of claim 32, wherein the matrix forming agent comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.

34. 34. The pharmaceutical composition of claim 32 or 33, wherein the matrix forming agent comprises a polypeptide.

35. The pharmaceutical composition of any one of claims 32 to 34, wherein the polypeptide comprises gelatin.

36. 36. The pharmaceutical composition of any one of claims 32-35, wherein the structure-forming agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.

37. 37. The pharmaceutical composition of any one of claims 32 to 36, wherein the structuring agent comprises mannitol.

38. A method of treating a patient comprising administering to the patient a therapeutic amount of a pharmaceutical composition according to any one of claims 15 to 37.

39. 39. The method of claim 38, wherein the patient is a human.

40. 1. A method for preparing a pharmaceutical composition comprising the steps of: coating the API particles with a coating material to form coated API particles, said coating material comprising one or more deformable components; applying a mechanical stress to the coated API particles to deform the one or more deformable components; coating said coated API particles with silica; applying a mechanical stress to at least one of adhere, partially embed or embed the silica onto the coated API particles; sieving the coated API particles to remove excess coating material, wherein the excess coating material comprises coating material that is not bound to the coated API particles; mixing the coated API particles into a matrix solution / suspension to form a pharmaceutical suspension; administering said pharmaceutical suspension into a mold.

41. 41. The method according to claim 40, wherein the dosage ratio used for combining said coated API particles with said matrix solution / suspension comprises 5-60% w / w of coated API particles and 40-96% w / w of matrix solution / suspension.

42. 43. The method according to claim 41 or 42, wherein the coating ratio used to combine the API particles with the coating material comprises 5-85% w / w of coating material and 15-95% w / w of uncoated API particles.

43. 43. The method of any one of claims 40-42, comprising freezing the administered suspension under sub-zero conditions and lyophilizing to form a lyophilized pharmaceutical composition.

44. The method of any one of claims 40 to 43, further comprising sieving the uncoated API particles.

45. The method of any one of claims 40 to 44, wherein sieving the coated API particles comprises passing the coated API particles through a device comprising two or more sieves.

46. The method of any one of claims 40 to 45, wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 75 μm or greater.

47. The method of any one of claims 40 to 46, wherein sieving the coated API particles comprises sieving the coated API particles to an average particle size of 200 μm or less.

48. 48. The method of any one of claims 40-47, wherein the API particles comprise one or more of an anti-inflammatory agent, an analgesic agent, an antipsychotic agent, an antiemetic agent, a laxative agent, an antidiarrheal agent, an antihistamine agent, or an antidepressant agent.

49. The method of any one of claims 40 to 48, wherein the coating material comprises silica as one or more of a protective coating or a flow aid.

50. The method of any one of claims 40 to 49, wherein the one or more deformable components of the coating material comprise a wax.

51. 51. The method of any one of claims 40 to 50, wherein the wax comprises one or more of carnauba wax, candelilla wax, or synthetic wax.

52. The method of any one of claims 40 to 51, wherein the matrix solution / suspension comprises a matrix-forming agent and a structure-forming agent.

53. 53. The method of claim 52, wherein the matrix forming agent comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, and acacia.

54. 54. The method of claim 52 or 53, wherein the matrix forming agent comprises a polypeptide.

55. 55. The method of claim 53 or 54, wherein the polypeptide comprises gelatin.

56. 56. The method of any one of claims 52 to 55, wherein the structuring agent comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.

57. 57. The method of any one of claims 52 to 56, wherein the structure-forming agent comprises mannitol.

Citation Information

Patent Citations

  • Rapidly disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

    JP2008526827A

  • Solvent-free mixing method for coating pharmaceutical components

    JP2015533162A

  • Minimizing agglomeration of drug particle coating materials during storage to stabilize drug disintegration times

    JP2022521317A

  • Minimize agglomeration of drug particle coating materials during storage to stabilize drug disintegration time

    JP7543291B2

  • Pharmaceutical and other dosage forms

    US5558880A

Cited By

  • Resin compositions, cured products, resin composite sheets, prepregs, metal foil-clad laminates, printed circuit boards, and semiconductor devices.

    JPWO2026083783A1